CCR2/CCR5 dual inhibitor Cenicriviroc inhibits the recruitment of Ly6Chi monocytes, thereby improving histological damage and fibrosis in the NASH model [51]. The gene discussed is CCR5; the disease is metabolic dysfunction-associated steatohepatitis.